Antibodies to interferon alpha in patients

  • G. Antonelli
  • F. Dianzani
Conference paper
Part of the Archives of Virology Supplementum book series (ARCHIVES SUPPL, volume 8)


A massive amount of information on interferons (IFNs) has been gathered since their original description as antiviral agents in 1957. Human IFNs have now been used clinically for over a decade and their therapeutic efficacy has been well established for some human neoplasias and viral diseases. During these studies, it has also been documented that some of the patients treated with IFNs can develop antibodies to IFNs which can affect their therapeutic efficacy. Here, it is summarized what is currently known on the biological and clinical aspects of these antibodies.


Hairy Cell Leukemia Hepatitis Patient Recombinant Interferon Essential Thrombocythaemia Essential Mixed Cryoglobulinemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Antonelli G, Currenti M, Turriziani O, Dianzani F (1990) Incidence of anti-IFN alpha neutralizing antibodies in hepatitis patients treated with different IFN alpha preparations. Antiviral Res 1: S104Google Scholar
  2. 2.
    Antonelli G, Currenti M, Turriziani O, Dianzani F (1991) Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 163: 882–885PubMedCrossRefGoogle Scholar
  3. 3.
    Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F (1992) Relative frequency of non-neutralizing antibodies to interferon in hepatitis patients treated with different IFN alpha preparations. J Infect Dis 165: 593PubMedCrossRefGoogle Scholar
  4. 4.
    Bendtzen K, Svenson M, Jonsson V, Hippe E (1990) Autoantibodies to cytokines: friends or foes? Immunol Today 11: 167–169PubMedCrossRefGoogle Scholar
  5. 5.
    Casato M, Laganä B, Antonelli G, Dianzani F, Bonomo L (1991) Long-term results of interferon therapy in essential mixed cryoglobulinemia. Blood 78: 1–6Google Scholar
  6. 6.
    Catani L, Gugliotta L, Zauli G, Bagnara GP, Antonelli G, Mattioli Belmonte M, Vianelli N, Bonsi L, Bruneiii MA, Tura S (1992) In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Haematology 77: 318–321Google Scholar
  7. 7.
    De Maeyer-Guignard J, De Maeyer E (1986) Natural antibodies to interferon-alpha and interferon-beta are a common feature of inbred mouse strains. J Immunol 136: 1708–1711PubMedGoogle Scholar
  8. 8.
    Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C (1990) Low incidence of neutralizing antibody formation to interferon in human recipients. J Interferon Res 9: S33–S36Google Scholar
  9. 9.
    Dianzani F, Antonelli G, Capobianchi MR (1990) The biological basis for clinical use of interferon. J Hepatol 11: S5–S10PubMedCrossRefGoogle Scholar
  10. 10.
    Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for highrisk malignant melanoma patients. Cancer 67: 2300PubMedCrossRefGoogle Scholar
  11. 11.
    Figlin RA, Itri LM (1989) Anti-interferon antibodies: a perspective. Semin Hematol 25: 9–15Google Scholar
  12. 12.
    Finter NB (1991) Why are there so many subtypes of alpha-interferons? J Interferon Res [Special issue, January] 185Google Scholar
  13. 13.
    Galton JE, Bedford P, Scott JE, Brand CM, Nethersell ABW (1990) Antibodies to lymphoblastoid interferon. Lancet 2: 572 - 573Google Scholar
  14. 14.
    Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnern E, Spiegel R, Tensen L, Burke JS, Vardiman JW (1988) Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa 2b. Semin Oncol 15: 7PubMedGoogle Scholar
  15. 15.
    Itri IM, Campion M, Dennin RA, Polleroni AV, Gutterman JU, Groopman JE, Trown PW (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alpha 2a by intramuscular injection. Cancer 59: 668–674PubMedCrossRefGoogle Scholar
  16. 16.
    Jacobs S, Friedman RM, Nagabhushan TL (1989) Detection of serum neutralizing antibodies to interferon alfa-2b (Intron A) by means of an enzyme immunoassay. J Interferon Res 9: S292Google Scholar
  17. 17.
    Leavitt R, Ratanantharathorn V, Ozer H, (1987) Alpha-2b interferon in the treatment of Hodgkins disease and non-Hodgkin’s lymphoma. Semin Oncol 14: 18–23PubMedGoogle Scholar
  18. 18.
    Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D (1992) Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J Infect Dis 165: 757 - 760PubMedCrossRefGoogle Scholar
  19. 19.
    Lok SF, Lai CL, Leung KY (1990) Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12: 1266PubMedCrossRefGoogle Scholar
  20. 20.
    Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G (1993) Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13: 146–150PubMedGoogle Scholar
  21. 21.
    Mogensen KE, Daubas PH, Gresser I, Sereni D, Varet B (1981) Patient with circulating antibodies to alpha interferon. Lancet ii: 1227–1228Google Scholar
  22. 22.
    Pestka S (1986) Interferon from 1981 to 1986. Methods Enzymol 119: 3–23PubMedCrossRefGoogle Scholar
  23. 23.
    Quesada JR, Hawkins M, Horning S, Alexantian R, Borden E, Merigan T, Adams F, Gutterman JU (1984) Collaborative phase I–II study of recombinant DNA- produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 77: 427–435PubMedCrossRefGoogle Scholar
  24. 24.
    Rosenblum MG, Unger BW, Gutterman JU, Hersh M, David GS, Frincke JM (1985) Modification of human lekocyte interferon pharmacology with a monoclonal antibody. Cancer Res 45: 2421PubMedGoogle Scholar
  25. 25.
    Ross C, Hansen MB, Schyberg T, Berg K (1990) Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 82: 57–62PubMedCrossRefGoogle Scholar
  26. 26.
    Sperber SJ, Gocke DJ, Haberzettl C, Kuk R, Schwartz B, Pestka S (1992) Anti- HIV-1 activity of recombinant and hybrid species of interferon-alpha. J Interferon Res 12: 363–368PubMedCrossRefGoogle Scholar
  27. 27.
    Spiegel J, Spicehandler JR, Jacobs SL, Oden EM (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (Intron A). Am J Med 80: 223–228PubMedCrossRefGoogle Scholar
  28. 28.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberber C, Longo DL (1988) Resistance to recombinant interferon alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Eng J Med 318: 1409–1413CrossRefGoogle Scholar
  29. 29.
    Vallbracht A, Treuner T, Flehming B, Joester KE, Miethammer D (1981) Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 287: 496–498CrossRefGoogle Scholar
  30. 30.
    von Wussow P, Hartman F, Freund M, Poliwoda H, Deicher H (1988) Leukocyte derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet i: 882–883CrossRefGoogle Scholar
  31. 31.
    von Wussow P, Freund M, Block B, Dietrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN alpha antibody during interferon therapy. Lancet ii: 635–636CrossRefGoogle Scholar
  32. 32.
    von Wussow P, Pralle H, Hochkeppel HK, Jakschies D, Sonnen S, Schmidt H, Muller-Rosenau D, Franke M, Haferlach T, Zwingers T, Rapp U, Deicher H (1991) Effective natural interferon-alpha therapy in recombinant interferon-alpha- resistant patients with hairy cell leukemia. Blood 78: 38–43Google Scholar
  33. 33.
    Zoon KC, Miller D, Bekisz J, zur Nedden D, Enterline JC, Nguyen NY, Ren-qui H (1992) Purification and characterization of multiple components of human lymphoblastoid interferon-alpha. J Biol Chem 267: 15210–15216PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • G. Antonelli
    • 1
  • F. Dianzani
    • 2
  1. 1.Department of Biomedicine, Sec. VirologyUniversity of PisaPisaItaly
  2. 2.Institute of VirologyUniversity “La Sapienza”RomeItaly

Personalised recommendations